|
[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136 (5) :e359-e386.
|
|
[2] ZHANG H, ZHANG H, LIU L, et al. An excerpt of AASLD guidelines for the treatment of hepatocellular carcinoma (2018) [J]. J Clin Hepatol, 2018, 34 (4) :743-748. (in Chinese) 张宏, 张浩, 琉璃.《2018年美国肝病学会肝细胞癌治疗指南》摘译[J].临床肝胆病杂志, 2018, 34 (4) :743-748.
|
|
[3] GILLIES RJ, GATENBY RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis[J]. Cancer Metastasis Rev, 2007, 26 (2) :311-317.
|
|
[4] SADRI NAHAND J, BOKHARAEI-SALIM F, SALMANINEJAD A, et al. microRNAs:Key players in virus-associated hepatocellular carcinoma[J]. J Cell Physiol, 2018, 234 (8) :12188-12225.
|
|
[5] SWITLIK WZ, BIELECKA-KOWALSKA A, KARBOWNIK MS, et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma:A preliminary study[J].Biomark Med, 2019, 13 (7) :523-534.
|
|
[6] ZHOU W, YANG WL, ZHANG HW, et al. Advances in the relationship between microRNA-483 and digestive system tumors[J]. Chin J Dig Surg, 2018, 17 (5) :522-526. (in Chinese) 周威, 杨万里, 张洪伟, 等.微RNA-483与消化系统肿瘤关系的研究进展[J].中华消化外科杂志, 2018, 17 (5) :522-526.
|
|
[7] BENJAMIN DI, CRAVATT BF, NOMURA DK. Global profiling strategies for mapping dysregulated metabolic pathways in cancer[J]. Cell Metab, 2012, 16 (5) :565-577.
|
|
[8] ORANG AV, PETERSEN J, MCKINNON RA, et al. Micromanaging aerobic respiration and glycolysis in cancer cells[J]. Mol Metab, 2019, 23:98-126.
|
|
[9] JAFARY F, GANJALIKHANY MR, MORADI A, et al. Novel peptide inhibitors for lactate dehydrogenase A (LDHA) :A survey to inhibit LDHA activity via disruption of protein-protein interaction[J]. Sci Rep, 2019, 9 (1) :4686.
|
|
[10] FU Y, SUN LQ, HUANG Y, et al. miR-142-3p inhibits the metastasis of hepatocellular carcinoma cells by regulating HMGB1 gene expression[J]. Curr Mol Med, 2018, 18 (3) :135-141.
|
|
[11] HUA S, LIU C, LIU L, et al. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA[J]. Biochem Biophys Res Commun, 2018, 496 (3) :947-954.
|
|
[12] IANSANTE V, CHOY PM, FUNG SW, et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation[J].Nat Commun, 2015, 6:7882.
|
|
[13] ZHAO R, LI L, YANG J, et al. Overexpression of pyruvate kinase M2 in tumor tissues is associated with poor prognosis in patients with hepatocellular carcinoma[J]. Pathol Oncol Res, 2019.[Epub ahead of print]
|
|
[14] CAO F, YIN LX. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/beta-catenin pathway[J]. Exp Mol Pathol, 2019, 106:34-43.
|
|
[15] TSAI WC, HSU SD, HSU CS, et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis[J].J Clin Invest, 2012, 122 (8) :2884-2897.
|
|
[16] VALDMANIS PN, KIM HK, CHU K, et al. miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression[J]. Nat Commun, 2018, 9 (1) :5321.
|
|
[17] LIU AM, XU Z, SHEK FH, et al. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma[J]. PLo S One, 2014, 9 (1) :e86872.
|
|
[18] DEWAAL D, NOGUEIRA V, TERRY AR, et al. Hexokinase-2depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J]. Nat Commun, 2018, 9 (1) :446.
|
|
[19] GUO W, QIU Z, WANG Z, et al. MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer[J].Hepatology, 2015, 62 (4) :1132-1144.
|
|
[20] ZHANG LF, LOU JT, LU MH, et al. Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma[J]. EMBO J, 2015, 34 (21) :2671-2685.
|
|
[21] KULSHRESHTHA R, FERRACIN M, WOJCIK SE, et al. A microRNA signature of hypoxia[J]. Mol Cell Biol, 2007, 27 (5) :1859-1867.
|
|
[22] MAHON PC, HIROTA K, SEMENZA GL. FIH-1:A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity[J]. Genes Dev, 2001, 15 (20) :2675-2686.
|
|
[23] CHEN Z, ZUO X, ZHANG Y, et al. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1alphamediated Warburg effect[J]. Cell Death Dis, 9 (5) :549.
|
|
[24] JIANG W, ZHANG L, GUO Q, et al. Identification of the pathogenic biomarkers for hepatocellular carcinoma based on RNAseq analyses[J]. Pathol Oncol Res, 2019, 25 (3) :1207-1213.
|
|
[25] LI B, HE L, ZUO D, et al. Mutual regulation of MiR-199a-5p and HIF-1alpha modulates the Warburg Effect in hepatocellular carcinoma[J]. J Cancer, 2017, 8 (6) :940-949.
|
|
[26] LI W, WANG J, CHEN QD, et al. Insulin promotes glucose consumption via regulation of miR-99a/m TOR/PKM2 pathway[J]. PLo S One, 2013, 8 (6) :e64924.
|
|
[27] YU XN, CHEN H, LIU TT, et al. Targeting the m TOR regulatory network in hepatocellular carcinoma:Are we making headway?[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871 (2) :379-391.
|
|
[28] JIA YY, ZHAO JY, LI BL, et al. miR-592/WSB1/HIF-1alpha axis inhibits glycolytic metabolism to decrease hepatocellular carcinoma growth[J]. Oncotarget, 2016, 7 (23) :35257-35269.
|
|
[29] BIE CQ, LIU XY, CAO MR, et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression[J]. Oncotarget, 2016, 7 (48) :79305-79318.
|
|
[30] GAO Y, ZHANG SG, WANG ZH, et al. Down-regulation of miR-342-3p in hepatocellular carcinoma tissues and its prognostic significance[J]. Eur Rev Med Pharmacol Sci, 2017, 21 (9) :2098-20102.
|
|
[31] LIU W, KANG L, HAN J, et al. miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect[J]. Onco Targets Ther, 2018, 11:1643-1653.
|
DownLoad: